The effect of a rapid molecular blood test on the use of antibiotics for nosocomial sepsis: a randomized clinical trial

Table 2 Antimicrobial consumption in DOT/1000 PD during the study

Antimicrobial consumption:	All patients			Positive test
Antimicrobial consumption:	Intervention group	Control group	P value	Intervention group	Control group	P value
DOT/1000 PD, median, (IQR)	(n = 100)	(n = 100)	P value	(n = 19)	(n = 25)	P value
- All antimicrobial	1621 (1196–2388)	2000 (1440–2433)	0.067*	1429 (1071–2000)	1889 (1357–2563)	0.017*
- Antimicrobial for Gram-negative bacteria coverage^a	1000 (768–1466)	1071 (786–1665)	0.248*	1071 (786–1429)	1286 (536–1857)	0.427*
- Antimicrobial for Gram-positive coverage^b	786 (554–1000)	866 (641–1000)	0.259*	71 (71–1000)	786 (354–1000)	0.013*

*Mann–Whitney test
IQR interquartile range
^aPiperacillin-tazobactam, fluoroquinolones, cephalosporins, aminoglycosides, tigecycline, trimethoprim-sulfamethoxazole, meropenem, polymyxin B/E
^bGlycopeptides, linezolid, daptomycin, andoxacillin

ISSN: 2052-0492